Studies drug resistance in tuberculosis using GeneXpert and Xpert tests
Observes how tuberculosis germs resist drugs in people aged 12 and older.
Plain-language title generated from the registry record
Registry title: Study About Drug Resistance of Mycobacterium Tuberculosis
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Sohag UniversitySohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07169149
- Record updated
- 11 September 2025
- Original description
Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases.Read full original descriptionShow less
Study of the Prevalence and Patterns of Drug Resistance of Mycobacterium Tuberculosis Using GeneXpert (MTB/RIF) and Xpert (MTB/XDR) Assays
Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is fundamental. Identifying the pattern of drug resistance will ensure that the most effective therapy can be selected. The aim of this study is to assess the prevalence and patterns of drug resistance of mycobacterium tuberculosis and to detect the possible risk factors associated with resistant cases.
Inclusion: geneXpert positive patients in pulmonary and extrapulmonary cases.
Exclusion: age below 12 years.